Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | TACR1 | P25103 | 2/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264469 | 1.00 | CTSL (0.61) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL2411802 | 0.89 | TACR1 (0.66) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7275662 | 0.89 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7275672 | 0.89 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL1264475 | 0.88 | CTSL (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL31397615 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL9088735 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10967811 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7281206 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL5484209 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157327-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2013087749-A1 | POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156865-A1 | POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-20 | — | — | US | disclosed |
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | ZIMMERMAN MARY P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6147188-A | IRREVERSIBLE CATHEPSIN OR CALPAIN INHIBITORS | PROTOTEK, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0863883-A1 | ALPHA-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC., (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0863883-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| US-5714484-A | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | PROTOTEK, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1996040647-A1 | α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | CPN1, CTRL, SERPINB1 | CTSL 116/4885CTSB 260/4885CTSS 176/4885 |
| US-20130156865-A1 | POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA | PDE4A, PDE4B, PDE4D | CTSL 2367/4885CTSB 3529/4885CTSS 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.